Lawrence S. Barak - Durham NC, US Michael A. Shetzline - Chapel Hill NC, US Robert H. Oakley - Durham NC, US Marc G. Caron - Hillsborough NC, US
International Classification:
C12Q 1/02 C12Q 1/44
US Classification:
435 19, 435 29
Abstract:
The present invention is related to the detection of GPCR ligands in a test sample by using a single cell biosensor expressing a GPCR. Preferably, the test sample is derived from a biological or environmental sample. This invention may be used to detect the presence of a disease or to detect the presence of a harmful agent in the environment. Included in the present invention is an array of biosensors that detect ligands of various GPCRs.
Single-Cell Biosensor For The Measurement Of Gpcr Ligands In A Test Sample
Lawrence S. Barak - Durham NC, US Michael A. Shetzline - Chapel Hill NC, US Robert H. Oakley - Durham NC, US Marc G. Caron - Hillsborough NC, US
Assignee:
Duke University - Durham NC
International Classification:
C12Q 1/46
US Classification:
435 20
Abstract:
The present invention is related to the detection of GPCR ligands in a test sample by using a single cell biosensor expressing a GPCR. Preferably, the test sample is derived from a biological or environmental sample. This invention may be used to detect the presence of a disease or to detect the presence of a harmful agent in the environment. Included in the present invention is an array of biosensors that detect ligands of various GPCRs.
- Basel, CH Michael SHETZLINE - Randolph NJ, US Andrew ZALEWSKI - Elkins Park PA, US
International Classification:
C07K 16/24
Abstract:
The present invention relates to an IL-1β binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
- Basel, CH Andrew Zalewski - Elkins Park PA, US Michael Shetzline - Randolph NJ, US
International Classification:
C07K 16/24 A61K 39/00
Abstract:
The present invention relates to an IL-1β binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
Tom Thuren - Succasunna NJ, US Andrew Zalewski - Elkins Park PA, US Michael Shetzline - Randolph NJ, US
Assignee:
Novartis AG - Basel
International Classification:
C07K 16/24
US Classification:
4241331, 4241581, 4241421, 5303892
Abstract:
The present invention relates to an IL-1β binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
News
Surprising monkey study could lead to 'functional' HIV cure
Fauci's visit was a first for Takeda, a company focused on treatments for cancer, gastroenterology and the central nervous system, said Dr. Michael Shetzline, who heads clinical science for Takeda in Cambridge.